Table 3

APS clinical manifestations

VariableSN-APS (n=67)SP-APS (n=87)p value
 Venous thrombosis27 (40.2%)40 (45.9%)0.51
 DVT21 (31.4%)27 (31.0%)0.96
 Recurrent DVT8 (38.0%)10 (37.0%)0.94
 PE16 (23.8%)25 (28.7%)0.58
 Recurrent PE5 (31.5%)2 (8.0%)0.08
Arterial thrombosis23 (34.3%)30 (34.4%)0.98
 Stroke10 (14.9%)15 (17.2%)0.82
 Recurrent stroke3 (30%)2 (13.3%)0.35
 Transient ischaemic attack (TIA)8 (11.9%)9 (10.3%)0.79
 Recurrent TIA1 (12.5%)3 (33.3%)0.57
 Coronary artery disease6 (8.9%)4 (4.6%)0.33
Pregnancy morbidity60/64 (93.7%)57/69 (82.6%)0.06
 <10th week spontaneous abortion43/64 (67.1%)36/69 (52.1%)0.11
 >10th week fetal loss40/64 (62.5%)41/69 (59.4%)0.72
 Prematurity <34th week18/64 (28.1%)15/69 (21.7%)0.42
 Pre-eclampsia18/64 (28.1%)16/69 (23.1%)0.55
  • APS, antiphospholipid syndrome; DVT, deep vein thrombosis; PE, pulmonary embolism; SN-APS, the so-called seronegative APS; SP-APS, seropositive APS.